Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
Apr 2023 |
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
Novel therapeutic choices in immune aplastic anemia |
Sep 2020 |
F1000Research |
Aplastic Anemia |
Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
Jul 2023 |
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
Newly revised 2023 MDS response criteria |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
New Approaches for Anemia in MDS |
Sep 2020 |
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes |
Jun 2023 |
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Myelodysplastic/myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U): More Than Just a "Catch-All" Term? |
Jun 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
Myelodysplastic Syndromes: Moving Towards Personalized Management |
May 2020 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
Nov 2020 |
Annals of Oncology: Official Journal of the European Society for Medical Oncology |
Myelodysplastic Syndromes (MDS) |